Reborna Biosciences, Inc. (Headquarters: Fujisawa City, Kanagawa Prefecture; Representative Director: Koji Fuji; hereinafter, “Reborna”) and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka City, Osaka Prefecture; President and COO: Toichi Takino; hereinafter, “Ono”) has entered into a research and licensing agreement on drug discovery in the field of central nervous system on March 31, 2025.

Under the terms of the agreement, Ono and Reborna will collaborate to discover RNA-targeting small molecule drugs for rare neurological disorders utilizing Reborna’s proprietary drug discovery platform. Ono will pay Reborna an upfront payment, as well as research expenses, research, development, and sales milestone payments, and tiered royalties based on net sales. Ono will retain the exclusive option right to develop, manufacture, and commercialize worldwide the development candidate compounds discovered through the research collaboration.

Reborna and Ono will combine their research and development capabilities to promote the research and development of drugs for rare neurological disorders under the agreement.

Comment from Seishi Katsumata, Corporate Officer / Executive Director, Discovery & Research, Ono Pharmaceutical Co., Ltd.
We highly value Reborna’s technology, which enables the regulation of targets that were previously difficult to address with conventional drug discovery methods by normalizing RNA function. We will work with Reborna to advance new drug discovery projects targeting difficult-to-treat rare neurological disorders, striving to deliver innovative new drugs to patients as soon as possible.

Comment from Koji Fuji, Representative Director of Reborna Biosciences, Inc.
We are delighted to initiate this research collaboration with Ono, which has a drug discovery policy of “creating original and breakthrough new drugs”, and to take a significant step forward in the discovery of drugs for rare diseases. We are committed to maximizing our drug discovery, research, and development capabilities and collaborating with Ono Pharmaceutical Co., Ltd. to create new drugs with high unmet medical needs.

About Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. Ono focuses its research on oncology, immunology, neurology, and specialty research with high medical needs as priority areas for the discovery and development of innovative medicines. For further information, please visit the company’s website at https://www.ono-pharma.com/en.

About Reborna Biosciences, Inc.
Reborna is engaged in drug discovery research for oral drugs that show disease-modifying effects through normalizing RNA function by using small molecule drugs with a high affinity for RNA. By targeting RNA that governs protein synthesis as a drug discovery target, we aim to provide drugs that offer a novel approach to diseases that have previously proven difficult to treat. We will contribute to society by providing new drugs that enable patients suffering from rare genetic diseases and their families to feel that they have been reborn.
For more information, please visit http://rebornabiosciences.com.